Gonterman Fernando
Department of Population Health Science & Policy, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Department of Counseling & Clinical Psychology, Teachers College Columbia University, New York, NY, USA.
Neuropsychiatr Dis Treat. 2023 Mar 8;19:565-577. doi: 10.2147/NDT.S388164. eCollection 2023.
The safety and efficacy of transcranial magnetic stimulation (TMS) in the acute treatment of major depressive disorder (MDD) is well established. However, it is not well understood which patient-related factors are associated with a more robust antidepressant response. Identifying predictive factors for therapeutic response to TMS treatment in depression will guide clinicians in patient selection.
By systematic review of clinical trial data, the current study aims to identify and analyze reported patient-specific predictors of response to an acute course of TMS treatment for MDD. PubMed was searched for randomized controlled trials of TMS for patients with depression. Studies were appraised for risk of bias using components recommended by the Cochrane Collaboration and the Preferred Reporting Items for Systematic Reviews and Meta-Analyses.
TMS data were available from 375 studies, 18 of which were included in this review. Treatment response is inversely associated with treatment refractoriness and age.
Inadequate sample size and large heterogeneity in study parameters among clinical trials limit any strong conclusions from being drawn; nonetheless, despite these limitations, there is mounting evidence, which points to age and treatment refractoriness as candidate variables for predicting clinical outcome. Implications of these findings for treatment of MDD are discussed.
经颅磁刺激(TMS)在重度抑郁症(MDD)急性治疗中的安全性和有效性已得到充分证实。然而,哪些患者相关因素与更强有力的抗抑郁反应相关,目前尚不清楚。确定抑郁症患者对TMS治疗反应的预测因素将指导临床医生进行患者选择。
通过对临床试验数据的系统评价,本研究旨在识别和分析已报道的MDD患者对TMS急性治疗疗程反应的特定患者预测因素。在PubMed上搜索TMS治疗抑郁症患者的随机对照试验。使用Cochrane协作网推荐的组成部分以及系统评价和Meta分析的首选报告项目对研究进行偏倚风险评估。
有375项研究提供了TMS数据,其中18项纳入了本综述。治疗反应与治疗难治性和年龄呈负相关。
临床试验中样本量不足和研究参数存在较大异质性限制了得出任何强有力的结论;尽管如此,尽管存在这些局限性,但越来越多的证据表明,年龄和治疗难治性是预测临床结果的候选变量。讨论了这些发现对MDD治疗的意义。